Neuroprotective effects of toll-like receptor 4 antagonism in spinal cord cultures and in a mouse model of motor neuron degeneration

Molecular Medicine

Volumn 18, Issue 6, 2012, Pages 971-981

  De Paola, Massimiliano ^a   Mariani, Alessandro ^a   Bigini, Paolo ^a   Peviani, Marco ^a,b   Ferrara, Giovanni ^a   Molteni, Monica ^a   Gemma, Sabrina ^a   Veglianese, Pietro ^a   Castellaneta, Valeria ^a   Boldrin, Valentina ^a   Rossetti, Carlo ^c   Chiabrando, Chiara ^a   Forloni, Gianluigi ^a   Mennini, Tiziana ^a   Fanelli, Roberto ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF INSUBRIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPOLYSACCHARIDE; NEUROPROTECTIVE AGENT; RILUZOLE; TOLL LIKE RECEPTOR 4; TOLL LIKE RECEPTOR 4 ANTAGONIST; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VB 3323;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; GRIP STRENGTH; HISTOLOGY; IMMUNOBLOTTING; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; MICROGLIA; MICROSCOPY; MOTONEURON DEGENERATION; MOUSE; NERVE CELL CULTURE; NERVE CELL DEGENERATION; NERVE CELL NECROSIS; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SPINAL CORD;

ANIMALS; CELL CULTURE TECHNIQUES; CELL SHAPE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; LIGANDS; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICE, NEUROLOGIC MUTANTS; MICROGLIA; MOTOR NEURONS; MUSCLES; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; NEUROTOXINS; SPINAL CORD; TOLL-LIKE RECEPTOR 4; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84865214998     PISSN: 10761551     EISSN: None     Source Type: Journal    
DOI: 10.2119/molmed.2012.00020     Document Type: Article

References (53)

1. Marsh BJ, Stevens SL, Hunter B, Stenzel-Poore MP. (2009) Inflammation and the emerging role of the toll-like receptor system in acute brain ischemia. Stroke. 40:S34-7.
2. Tahara K, et al. (2006) Role of toll-like receptor signalling in Abeta uptake and clearance. Brain. 129:3006-19.
3. Chakravarty S, Herkenham M. (2005) Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci. 25:1788-96.
4. Tang SC, et al. (2008) Toll-like receptor-4 mediates neuronal apoptosis induced by amyloid betapeptide and the membrane lipid peroxidation product 4-hydroxynonenal. Exp. Neurol. 213:114-21.
5. Abate W, Alghaithy AA, Parton J, Jones KP, Jackson SK. (2009) Surfactant lipids regulate LPS- induced interleukin-8 production in A549 lung epithelial cells by inhibiting translocation of TLR4 into lipid raft domains. J. Lipid Res. 51:334-44.
6. Hoshino K, et al. (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the Lps gene product. J. Immunol. 162:3749-52.
7. Takeda K, Akira S. (2001) Roles of Toll-like receptors in innate immune responses. Genes Cells. 6:733-42.
8. Flo TH, et al. (2000) Involvement of CD14 and beta2-integrins in activating cells with soluble and particulate lipopolysaccharides and mannuronic acid polymers. Infect. Immun. 68:6770-6.
9. Tobias PS, Tapping RI, Gegner JA. (1999) Endotoxin interactions with lipopolysaccharideresponsive cells. Clin. Infect. Dis. 28:476-81.
10. Muller-Loennies S, et al. (1998) What we know and don't know about the chemical and physical structure of lipopolysaccharide in relation to biological activity. Prog. Clin. Biol. Res. 397:51-72.
11. Lien E, et al. (2000) Toll-like receptor 4 imparts ligand-specific recognition of bacterial lipopolysaccharide. J. Clin. Invest. 105:497-504.
12. Shimazu R, et al. (1999) MD-2, a molecule that confers lipopolysaccharide responsiveness on Toll-like receptor 4. J. Exp. Med. 189:1777-82.
13. Walter S, et al. (2007) Role of the toll-like receptor 4 in neuroinflammation in Alzheimer's disease. Cell Physiol. Biochem. 20:947-56.
14. Panaro MA, et al. (2008) Expression of TLR4 and CD14 in the central nervous system (CNS) in a MPTP mouse model of Parkinson's-like disease. Immunopharmacol. Immunotoxicol. 30:729-40.
15. Bsibsi M, Ravid R, Gveric D, van Noort JM. (2002) Broad expression of Toll-like receptors in the human central nervous system. J. Neuropathol. Exp. Neurol. 61:1013-21.
16. Letiembre M, et al. (2009) Screening of innate immune receptors in neurodegenerative diseases: a similar pattern. Neurobiol. Aging. 30:759-68.
17. Casula M, et al. (2011) Toll-like receptor signaling in amyotrophic lateral sclerosis spinal cord tissue. Neuroscience. 179:233-43.
18. Schmitt-John T, et al. (2005) Mutation of Vps54 causes motor neuron disease and defective spermiogenesis in the wobbler mouse. Nat. Genet. 37:1213-5.
19. Liewen H, et al. (2005) Characterization of the human GARP (Golgi associated retrograde protein) complex. Exp. Cell Res. 306:24-34.
20. Beghi E, Mennini T. (2004) Basic and clinical research on amyotrophic lateral sclerosis and other motor neuron disorders in Italy: recent findings and achievements from a network of laboratories. Neurol. Sci. 25 (Suppl. 2):S41-60.
21. Bigini P, Bastone A, Mennini T. (2001) Glutamate transporters in the spinal cord of the wobbler mouse. Neuroreport. 12:1815-20.
22. Boillee S, Viala L, Peschanski M, Dreyfus PA. (2001) Differential microglial response to progressive neurodegeneration in the murine mutant Wobbler. Glia. 33:277-87.
23. Rathke-Hartlieb S, Schmidt VC, Jockusch H, Schmitt-John T, Bartsch JW. (1999) Spatiotemporal progression of neurodegeneration and glia activation in the wobbler neuropathy of the mouse. Neuroreport. 10:3411-6.
24. Schlomann U, Rathke-Hartlieb S, Yamamoto S, Jockusch H, Bartsch JW. (2000) Tumor necrosis factor alpha induces a metalloproteasedisintegrin, ADAM8 (CD 156): implications for neuron-glia interactions during neurodegeneration. J. Neurosci. 20:7964-71.
25. D.L. no. 116, G.U. suppl. 40, 18 February 1992.
26. Circolare no. 8, G.U., 14 Luglio 1994.
27. EEC Council Directive 86/609, OJ L 358, 1, Dec. 12, 1987.
28. Institute of Laboratory Animal Resources; Commission on Life Sciences; National Research Council. (1996) Guide for the Care and Use of Laboratory Animals. Washington (DC): National Academy Press. [cited 2012 Jul 30]. Available from: http://www.nap.edu/openbook.php?record_id=5140
29. De Paola M, Diana V, Bigini P, Mennini T. (2008) Morphological features and responses to AMPA receptor-mediated excitotoxicity of mouse motor neurons: comparison in purified, mixed anterior horn or motor neuron/glia cocultures. J. Neurosci. Methods. 170:85-95.
30. Hamby ME, Uliasz TF, Hewett SJ, Hewett JA. (2006) Characterization of an improved procedure for the removal of microglia from confluent monolayers of primary astrocytes. J. Neurosci. Methods. 150:128-37.
31. Gingras M, Gagnon V, Minotti S, Durham HD, Berthod F. (2007) Optimized protocols for isolation of primary motor neurons, astrocytes and microglia from embryonic mouse spinal cord. J. Neurosci. Methods. 163:111-18.
32. Macagno A, et al. (2006) A cyanobacterial LPS antagonist prevents endotoxin shock and blocks sustained TLR4 stimulation required for cytokine expression. J. Exp. Med. 203:1481-92.
33. Jemmett K, et al. (2008) A cyanobacterial lipopolysaccharide antagonist inhibits cytokine production induced by Neisseria meningitidis in a human whole-blood model of septicemia. Infect. Immun. 76:3156-63.
34. Blesch A. (2004) Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods. 33:164-72.
35. Fumagalli E, Bigini P, Barbera S, De Paola M, Mennini T. (2006) Riluzole, unlike the AMPA antagonist RPR119990, reduces motor impairment and partially prevents motoneuron death in the wobbler mouse, a model of neurodegenerative disease. Exp. Neurol. 198:114-28.
36. Bigini P, Mennini T. (2004) Immunohistochemical localization of TNFalpha and its receptors in the rodent central nervous system. Methods Mol. Med. 98:73-80.
37. Bigini P, et al. (2007) Lack of caspase-dependent apoptosis in spinal motor neurons of the wobbler mouse. Neurosci. Lett. 426:106-10.
38. Bigini P, et al. (2008) Recombinant human TNF-binding protein-1 (rhTBP-1) treatment delays both symptoms progression and motor neuron loss in the wobbler mouse. Neurobiol. Dis. 29:465-76.
39. Lehnardt S, et al. (2002) The toll-like receptor TLR4 is necessary for lipopolysaccharideinduced oligodendrocyte injury in the CNS. J. Neurosci. 22:2478-86.
40. Wood PL. (1995) Microglia as a unique cellular target in the treatment of stroke: potential neurotoxic mediators produced by activated microglia. Neurol. Res. 17:242-8.
41. Madrigal JL, Feinstein DL, Dello Russo C. (2005) Norepinephrine protects cortical neurons against microglial-induced cell death. J. Neurosci. Res. 81:390-6.
42. Heneka MT, et al. (2002) Noradrenergic depletion potentiates beta-amyloid-induced cortical inflammation: implications for Alzheimer's disease. J. Neurosci. 22:2434-42.
43. Banks WA, Erickson MA. (2010) The blood-brain barrier and immune function and dysfunction. Neurobiol. Dis. 37:26-32.
44. Maroso M, et al. (2010) Toll-like receptor 4 and high-mobility group box-1 are involved in ictogenesis and can be targeted to reduce seizures. Nat. Med. 16:413-9.
45. Christianson CA, et al. (2011) Spinal TLR4 mediates the transition to a persistent mechanical hypersensitivity after the resolution of inflammation in serum-transferred arthritis. Pain. 152:2881-91.
46. Mazarati A, Maroso M, Iori V, Vezzani A, Carli M. (2011) High-mobility group box-1 impairs memory in mice through both toll-like receptor 4 and receptor for advanced glycation end products. Exp. Neurol. 232:143-8.
47. Netea MG, van Deuren M, Kullberg BJ, Cavaillon JM, Van der Meer JW. (2002) Does the shape of lipid A determine the interaction of LPS with Toll-like receptors? Trends Immunol. 23:135-9.
48. Alexianu ME, Kozovska M, Appel SH. (2001) Immune reactivity in a mouse model of familial ALS correlates with disease progression. Neurology. 57:1282-9.
49. Tortarolo M, et al. (2003) Persistent activation of p38 mitogen-activated protein kinase in a mouse model of familial amyotrophic lateral sclerosis correlates with disease progression. Mol. Cell. Neurosci. 23:180-92.
50. Yoshihara T, et al. (2002) Differential expression of inflammation- and apoptosis-related genes in spinal cords of a mutant SOD1 transgenic mouse model of familial amyotrophic lateral sclerosis. J. Neurochem. 80:158-67.
51. Bensimon G, Lacomblez L, Meininger V. (1994) A controlled trial of riluzole in amyotrophic lateral sclerosis: ALS/Riluzole Study Group. N. Engl. J. Med. 330:585-91.
52. Lacomblez L, Bensimon G, Leigh PN, Guillet P, Meininger V. (1996) Dose-ranging study of riluzole in amyotrophic lateral sclerosis: Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 347:1425-31.
53. Miller RG, Mitchell JD, Lyon M, Moore DH. (2003) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Amyotroph. Lateral Scler. Other Motor Neuron Disord. 4:191-206.